Caris Life Sciences, Inc.

CAI · Nasdaq · ·

对比

US$23.05-3.8%11月13日收盘

数据截至2026年9月30日，来自2026年11月4日提交的10-Q

1W: -8.6%
1M: -27.4%
3M: +5.7%

Caris Life Sciences, Inc.（CAI）股票——这是一门好生意吗？ — InspectStocks

Caris Life Sciences, Inc.

CAI · Nasdaq · ·

对比

US$23.05-3.8%11月13日收盘

数据截至2026年9月30日，来自2026年11月4日提交的10-Q

1W: -8.6%
1M: -27.4%
3M: +5.7%

Just reported

Q3 2026 results

From Caris Life Sciences's results release of 2026年11月4日; its quarterly report has since been filed.

Revenue
Actual
US$275.4M
+27% y/y
+4.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$0.05
-38% y/y
Guided
—
No guide given
Operating income, GAAP
Actual
US$19.3M
-41% y/y
-28% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$1.04B – US$1.05B+29% y/y Raised +1.0%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Caris Life Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 352 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

怎么赚钱

Molecular profiling services97%
Pharma research and development services4%

各项收入占比是对six months ended June 30, 2026的估算，并非来自已提交报告的数字。

竞争对手

RHHBYFoundation Medicine (a Roche subsidiary)
TEMTempus AI
C
规模
US$13.1B
利润率
-12.5%
GHGuardant Health
B
规模
US$20.5B
利润率
-37.9%
NTRANatera
B
规模
US$46.3B
利润率
-5.7%
GRALGRAIL
D
规模
US$5.2B
利润率
-243.8%
PSNLPersonalis
D
规模
US$1.7B
利润率
-147.7%

卖什么6

MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.

再显示 3 项

Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.

谁在买4

Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
Government and commercial health insurers pay for some patient tests when they cover the test and its use.
Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
Academic cancer centers and researchers use Caris data and collaborate on cancer research.

靠什么支撑，什么会击垮它

业务依赖什么

1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.

可能出什么问题

1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.

完整财务报表 →

关于Caris Life Sciences, Inc.

Caris analyzes DNA and RNA from cancer tissue and blood to find molecular features that may help doctors choose treatments. Its tests examine the whole exome—the protein-coding parts of DNA—or the whole transcriptome, and the company uses artificial intelligence (AI) and machine learning (ML) to interpret results. Caris also provides data and research services to drug companies and uses patient samples and data to investigate potential cancer drug targets.

总部: Irving, Texas
成立于: 2008
上市于: Nasdaq
财年结束: December 31

基于 Caris Life Sciences, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。

Just reported